Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants
Status:
Completed
Trial end date:
2023-09-06
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, fixed-sequence, Phase 1 study in healthy adult
participants to evaluate the effect of AGMB-129 200 mg twice daily (BID) on the PK of a
single dose of MDZ in healthy participants.
A total of 14 participants will be enrolled and will receive study intervention in a
fixed-sequence scheme. All IP will be administered orally and in fed conditions.
The total duration of involvement for each participant, screening through follow-up, will be
approximately 6 weeks.